Cytokinetics (KK3A) Stock Price & Analysis
KK3A Stock Chart & Stats
- Day’s Range
- EUR 56.38 - EUR 56.62
- 52-Week Range
- EUR 48.56 - EUR 77.30
- Previous Close
- EUR 57.04
- Volume
- N/A
- Average Volume (3M)
- 53
- Market Cap
- EUR 7.84B
- Enterprise Value
- EUR 11.35B
- Total Cash (Recent Filing)
- EUR 1.17B
- Total Debt (Recent Filing)
- EUR 1.27B
- Price to Earnings (P/E)
- ―
- Beta
- 0.14
- Next Earnings
- Nov 04, 2026 (Est.)
- EPS Estimate
- -1.29
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Commercial Launch Traction
MYQORZO is showing tangible early adoption, with rapidly rising dispensed patients, expanding prescriber reach, and increasing prescription growth. This provides a developing commercial foundation and could support more durable product revenue as awareness, access, and physician familiarity improve.
Late-Stage Clinical And Regulatory Progress
Positive pivotal data and defined regulatory milestones strengthen Cytokinetics' path toward expanding aficamten across hypertrophic cardiomyopathy. Success in additional indications could broaden the addressable market, extend the franchise, and improve the company's future commercial scale.
Improved Liquidity
The financing materially increased available liquidity, giving Cytokinetics greater capacity to fund commercialization, regulatory filings, and late-stage clinical programs. A larger cash buffer can support execution through upcoming milestones and reduce near-term dependence on additional financing.
Bears Say
Heavy Cash Burn And Losses
Large recurring cash outflows and continuing losses mean Cytokinetics must consume substantial resources before its commercial portfolio can become self-funding. Persistent negative cash generation increases funding needs and makes execution on launches and trials financially demanding.
Volatile Revenue Base
The sharp revenue decline shows that reported results remain sensitive to irregular collaboration and milestone payments rather than being supported solely by recurring product sales. This volatility complicates financial planning and leaves near-term growth dependent on commercial adoption and future deal events.
Pressured Capital Structure
Negative equity combined with substantial debt indicates a financially pressured capital structure and limits balance-sheet flexibility. Even with improved cash from the offering, the company remains reliant on successful commercialization and capital access to support obligations and ongoing investment.
Cytokinetics News
KK3A FAQ
What was Cytokinetics’s price range in the past 12 months?
What is Cytokinetics’s market cap?
When is Cytokinetics’s upcoming earnings report date?
How were Cytokinetics’s earnings last quarter?
Is Cytokinetics overvalued?
Does Cytokinetics pay dividends?
What is Cytokinetics’s EPS estimate?
How many shares outstanding does Cytokinetics have?
What happened to Cytokinetics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cytokinetics?
What is the TipRanks Smart Score and how is it calculated?
Cytokinetics Stock Smart Score
Company Description
Cytokinetics
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Robert I. Blum
- Employees
- 673
- Website
- www.cytokinetics.com
- Address
- 350 Oyster Point Boulevard, South San Francisco, CA, 94080, US
Cytokinetics (KK3A) Earnings & Revenues
KK3A Earnings Call
Earnings Call SentimentPositive
The call conveyed substantial operational and clinical progress: strong early commercial momentum for MYQORZO (rapidly growing prescriptions, rising awareness, >700 prescribers and >1,500 dispensed patients), pivotal ACACIA-HCM positive results with planned sNDA submission, successful European regulatory steps and a $760M financing that boosted cash to ~$1.7B. These strategic and scientific achievements were balanced against near-term financial headwinds including a YOY revenue decline driven by absence of milestone revenue, a wider GAAP net loss ($198.8M), sharply higher SG&A tied to launch costs and upwardly revised 2026 expense guidance. Overall, the operational wins, pivotal data and strong cash position indicate a constructive outlook for growth and future approvals, though investors should expect continued elevated spending as the company scales commercialization and pursues regulatory filings.
View all DE:KK3A earnings summariesKK3A Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 6 | 8 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 6 | 0 | 6 |
